^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    M4112

    i
    Other names: M4112, M 4112, MS 201408-0005A, M-4112, MS201408-0005
    Associations

    News

    Trials
    Company:
    EMD Serono
    Drug class:
    IDO1 inhibitor, Tryptophan 2,3-dioxygenase inhibitor
    Related drugs:
    Associations

    News

    Trials
    4years
    Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors. (PubMed, J Immunother Cancer)
    There were no serious safety concerns at any dose. Although M4112 inhibited IDO1 activity ex vivo, plasma kynurenine levels were not reduced despite achieving target exposure.Trial registration number NCT03306420.
    P1 data • Journal
    |
    IDO1 (Indoleamine 2,3-dioxygenase 1)
    |
    IDO1 expression
    |
    M4112